Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 13,517 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Clear all
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04200456
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 27, 2026, 11:45 AM EDT
Completed No phase listed Observational

Collection of Blood Samples for DNA in Motor Neuron Disease

NCT00362362
View directory record Official record
Conditions
Motor Neuron Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 11:45 AM EDT
Recruiting Not applicable Interventional

Technology-enabled Management Versus Usual Care for Blood Pressure

NCT05479461
View directory record Official record
Conditions
Hypertension
Interventions
Digital Hypertension Management System, Usual Care
Other
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Eatonton, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 27, 2026, 11:45 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

SEPA+PrEP-Women Pilot Trial for HIV Prevention Among Women at Risk for HIV

NCT07864766
View directory record Official record
Conditions
HIV Infections
Interventions
SEPA+PrEP Women
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

The Pathophysiology of Orthostatic Hypotension

NCT00748059
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions
Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 27, 2026, 11:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Glendale, Arizona • Glendale, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

NCT00087646
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 27, 2026, 11:45 AM EDT
Completed No phase listed Observational

Body Structures Determining Differences in Forearm and Upper Arm Blood Pressures

NCT01087827
View directory record Official record
Conditions
Blood Pressure
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate

NCT03234361
View directory record Official record
Conditions
Hypertension
Interventions
High Phosphate Phase, Low Phosphate Phase
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 27, 2026, 11:45 AM EDT
Recruiting Phase 2 Interventional

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

NCT01053741
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 27, 2026, 11:45 AM EDT
Terminated Phase 1 Interventional

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

NCT01403922
View directory record Official record
Conditions
Chronic Hypertension
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Overland Park, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

NCT04201496
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Combination Product · Device
Lead sponsor
Ananda Basu, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy

NCT00593242
View directory record Official record
Conditions
Neonatal Hypoxic Ischemic Encephalopathy
Interventions
infusion of autologous cord blood, Neurodevelopmental outcomes
Biological · Other
Lead sponsor
Michael Cotten
Other
Eligibility
Up to 14 Days
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

NCT00262886
View directory record Official record
Conditions
Kidney Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

NCT02762370
View directory record Official record
Conditions
Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Interventions
FX006 32 mg, TCA IR 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
Anaheim, California • El Cajon, California • North Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 27, 2026, 11:45 AM EDT
Completed No phase listed Observational

Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients

NCT00918073
View directory record Official record
Conditions
HIV Infections, Smokers
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Not applicable Interventional

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

NCT01410123
View directory record Official record
Conditions
Liver Diseases, Alcoholic, Alcoholism, HIV, Hepatitis C
Interventions
Integrated Stepped Care (ISC), Treatment as Usual
Other
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Not applicable Interventional

Galectin-3 Blockade in Patients With High Blood Pressure

NCT01960946
View directory record Official record
Conditions
Hypertension
Interventions
Modified Citrus Pectin (MCP) vs placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 27, 2026, 11:45 AM EDT
Withdrawn Phase 2 Interventional

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

NCT00528827
View directory record Official record
Conditions
Hypertension
Interventions
Cardene® I.V.
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 27, 2026, 11:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Training on Upper Extremity Grip Strength

NCT06535373
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Blood flow restriction
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 27, 2026, 11:45 AM EDT
Completed Phase 3 Interventional

A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies

NCT00000869
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 27, 2026, 11:45 AM EDT